Literature DB >> 33580974

Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia.

Shiyuan Wang1, Xue Wang1, Chunying Ye1, Hai Cheng1, Ming Shi2, Wei Chen1, Kunming Qi1, Gang Wang2, Qingyun Wu3, Lingyu Zeng3, Zhenyu Li1, Guangjun Jing4, Junnian Zheng2,5,6, Kailin Xu1,3, Jiang Cao1.   

Abstract

Entities:  

Year:  2021        PMID： 33580974     DOI： 10.1002/ajh.26123

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

Review 1.  Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era.

Authors:  Shang Mengxuan; Zhou Fen; Jin Runming
Journal:  Front Pediatr       Date:  2022-06-23       Impact factor: 3.569

2.  Humanized Chimeric Antigen Receptor (CAR) T cells.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Roddy S O'Connor
Journal:  J Cancer Immunol (Wilmington)       Date:  2021

3.  Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.

Authors:  Wei Chen; Yuhan Ma; Ziyuan Shen; Huimin Chen; Ruixue Ma; Dongmei Yan; Ming Shi; Xiangmin Wang; Xuguang Song; Cai Sun; Jiang Cao; Hai Cheng; Feng Zhu; Haiying Sun; Depeng Li; Zhenyu Li; Junnian Zheng; Kailin Xu; Wei Sang
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

4.  [Consensus of Chinese experts on chimeric antigen receptor T cell therapy for adult acute B-cell lymphoblastic leukemia (2022)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-02-14

5.  Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains.

Authors:  Yupanun Wutti-In; Jatuporn Sujjitjoon; Nunghathai Sawasdee; Aussara Panya; Katesara Kongkla; Pornpimon Yuti; Petlada Yongpitakwattana; Chutamas Thepmalee; Mutita Junking; Thaweesak Chieochansin; Naravat Poungvarin; Montarop Yamabhai; Pa-Thai Yenchitsomanus
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.